Home » Topics » Science » New compound

New compound
RSS

BCL6 PROTAC degrader ARVN-71228 shows efficacy in preclinical models of DLBCL

Dec. 15, 2021

[68Ga]SP-94 shows excellent uptake in GRP78-positive HCC tumors

Dec. 2, 2021

Discovery of the novel BCL6 BTB-specific inhibitor, AP-4-287

Nov. 29, 2021

CT-859 improves survival in a murine NASH model

Nov. 26, 2021

PCC-0105002 attenuates neuropathic pain without motor coordination-associated side effects

Nov. 25, 2021

GNE-502 shows promising efficacy in breast tumor xenograft model

Nov. 24, 2021

Potent non-HAP class I HBV capsid assembly modulator ALG-005398 reduces HBsAg levels in vivo

Nov. 22, 2021

Novel STING agonist RVU-27065 shows potency in EMT6 breast cancer model

Nov. 18, 2021

PCC-1, an orally active HPK1 inhibitor with strong antitumor activity

Nov. 18, 2021

Novel pan-ERR agonists can provide cardioprotection against heart failure

Nov. 17, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...